Using MBMA to Run Virtual “Head-to-head Trials”

Certara Strategic Consulting scientists used model-based meta-analysis to compare an approved osteoporosis drug to competing drugs in the same indication. The sponsor needed to compare denosumab—an osteoporosis drug—to competing drugs in the same landscape. Certara Strategic Consulting scientists used model-based meta-analysis (MBMA) to run virtual “head-to-head trials” of denosumab and other approved osteoporosis treatments. The MBMA analysis provided insight into how denosumab compares to other drugs approved for this indication without having to spend the time and money on running head-to-head trials.

Learn More LinkedIn Twitter Facebook Email